Search

Your search keyword '"Parnetti L"' showing total 838 results
Start Over Author "Parnetti L"
838 results on '"Parnetti L"'

151. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

Author

Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S.D., Bernardini, S., Bocchio-Chiavetto, L., Blankenstein, M.A., Carrillo, M.C., Chalbot, S., Coart, E., Chiasserini, D., Cutler, N., Dahlfors, G., Duller, S., Fagan, A.M., Forlenza, O., Frisoni, G.B., Galasko, D., Galimberti, D., Hampel, H., Handberg, A., Heneka, M.T., Herskovits, A.Z., Herukka, S.K., Holtzman, D.M., Humpel, C., Hyman, B.T., Iqbal, K., Jucker, M., Kaeser, S.A., Kaiser, E., Kapaki, E., Kidd, D., Klivenyi, P., Knudsen, C.S., Kummer, M.P., Lui, J., Llado, A., Lewczuk, P., Li, Q.X., Martins, R., Masters, C., McAuliffe, J., Mercken, M., Moghekar, A., Molinuevo, J.L., Montine, T.J., Nowatzke, W., O'Brien, R., Otto, M., Paraskevas, G.P., Parnetti, L., Petersen, R.C., Prvulovic, D., Reus, H.P.M. de, Rissman, R.A., Scarpini, E., Stefani, A., Soininen, H., Schroder, J., Shaw, L.M., Skinningsrud, A., Skrogstad, B., Spreer, A., Talib, L., Teunissen, C., Trojanowski, J.Q., Tumani, H., Umek, R.M., Broeck, B. Van, Vanderstichele, H., Vecsei, L., Verbeek, M.M., Windisch, M., Zhang, J., Zetterberg, H., Blennow, K., Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S.D., Bernardini, S., Bocchio-Chiavetto, L., Blankenstein, M.A., Carrillo, M.C., Chalbot, S., Coart, E., Chiasserini, D., Cutler, N., Dahlfors, G., Duller, S., Fagan, A.M., Forlenza, O., Frisoni, G.B., Galasko, D., Galimberti, D., Hampel, H., Handberg, A., Heneka, M.T., Herskovits, A.Z., Herukka, S.K., Holtzman, D.M., Humpel, C., Hyman, B.T., Iqbal, K., Jucker, M., Kaeser, S.A., Kaiser, E., Kapaki, E., Kidd, D., Klivenyi, P., Knudsen, C.S., Kummer, M.P., Lui, J., Llado, A., Lewczuk, P., Li, Q.X., Martins, R., Masters, C., McAuliffe, J., Mercken, M., Moghekar, A., Molinuevo, J.L., Montine, T.J., Nowatzke, W., O'Brien, R., Otto, M., Paraskevas, G.P., Parnetti, L., Petersen, R.C., Prvulovic, D., Reus, H.P.M. de, Rissman, R.A., Scarpini, E., Stefani, A., Soininen, H., Schroder, J., Shaw, L.M., Skinningsrud, A., Skrogstad, B., Spreer, A., Talib, L., Teunissen, C., Trojanowski, J.Q., Tumani, H., Umek, R.M., Broeck, B. Van, Vanderstichele, H., Vecsei, L., Verbeek, M.M., Windisch, M., Zhang, J., Zetterberg, H., and Blennow, K.

Abstract

Contains fulltext : 98400.pdf (publisher's version ) (Closed access), BACKGROUND: The cerebrospinal fluid (CSF) biomarkers amyloid beta (Abeta)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program. METHODS: The program is open for laboratories using commercially available kits for Abeta, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Molndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples. RESULTS: Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure Abeta-(1-42), P-tau(181P), and T-tau), and 5 used Meso Scale Discovery with the Abeta triplex (AbetaN-42, AbetaN-40, and AbetaN-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories. CONCLUSIONS: Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.

Published
2011

152. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

Author

Verwey, N. A., van der Flier, W M, Blennow, K, Clark, C, Sokolow, S, De Deyn, P P, Galasko, D, Hampel, H, Hartmann, T, Kapaki, E, Lannfelt, Lars, Mehta, P D, Parnetti, L, Petzold, A, Pirttila, T, Saleh, L, Skinningsrud, A, Swieten, J C V, Verbeek, M M, Wiltfang, J, Younkin, S, Scheltens, P, Blankenstein, M A, Verwey, N. A., van der Flier, W M, Blennow, K, Clark, C, Sokolow, S, De Deyn, P P, Galasko, D, Hampel, H, Hartmann, T, Kapaki, E, Lannfelt, Lars, Mehta, P D, Parnetti, L, Petzold, A, Pirttila, T, Saleh, L, Skinningsrud, A, Swieten, J C V, Verbeek, M M, Wiltfang, J, Younkin, S, Scheltens, P, and Blankenstein, M A

Abstract

BACKGROUND: Different cerebrospinal fluid (CSF) amyloid-beta 1-42 (Abeta(1-42)), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres. METHODS: Three CSF-pool samples were distributed to 13 laboratories in 2004 and the same samples were again distributed to 18 laboratories in 2008. In 2004 six laboratories measured Abeta(1-42), Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex. RESULTS: In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for Abeta(1-42), Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotest((R)) (N = 13) for Abeta(1-42), lower interCV were calculated (22%). The centres that participated in both years (N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008. CONCLUSIONS: The highest variability was found for Abeta(1-42). The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.

Published
2009
Full Text
View/download PDF

153. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.

Author

Verwey, N.A., Flier, W.M. van der, Blennow, K., Clark, C., Sokolow, S., Deyn, P.P. de, Galasko, D., Hampel, H., Hartmann, T., Kapaki, E., Lannfelt, L., Mehta, P.D., Parnetti, L., Petzold, A., Pirttilä, T., Saleh, L., Skinningsrud, A., Swieten, J.C. van, Verbeek, M.M., Wiltfang, J., Younkin, S., Scheltens, P., Blankenstein, M.A., Verwey, N.A., Flier, W.M. van der, Blennow, K., Clark, C., Sokolow, S., Deyn, P.P. de, Galasko, D., Hampel, H., Hartmann, T., Kapaki, E., Lannfelt, L., Mehta, P.D., Parnetti, L., Petzold, A., Pirttilä, T., Saleh, L., Skinningsrud, A., Swieten, J.C. van, Verbeek, M.M., Wiltfang, J., Younkin, S., Scheltens, P., and Blankenstein, M.A.

Abstract

Item does not contain fulltext, BACKGROUND: Different cerebrospinal fluid (CSF) amyloid-beta 1-42 (Abeta(1-42)), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres. METHODS: Three CSF-pool samples were distributed to 13 laboratories in 2004 and the same samples were again distributed to 18 laboratories in 2008. In 2004 six laboratories measured Abeta(1-42), Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex. RESULTS: In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for Abeta(1-42), Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotest (N = 13) for Abeta(1-42), lower interCV were calculated (22%). The centres that participated in both years (N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008. CONCLUSIONS: The highest variability was found for Abeta(1-42). The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.

Published
2009

154. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Author

Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.K., Flier, W.M. van der, Blankenstein, M.A., Ewers, M., Rich, K., Kaiser, E., Verbeek, M.M., Tsolaki, M., Mulugeta, E., Rosen, E., Aarsland, D., Visser, P.J., Schroder, J., Marcusson, J., Leon, M., Hampel, H., Scheltens, P., Pirttilä, T., Wallin, A., Jonhagen, M.E., Minthon, L., Winblad, B., Blennow, K., Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.K., Flier, W.M. van der, Blankenstein, M.A., Ewers, M., Rich, K., Kaiser, E., Verbeek, M.M., Tsolaki, M., Mulugeta, E., Rosen, E., Aarsland, D., Visser, P.J., Schroder, J., Marcusson, J., Leon, M., Hampel, H., Scheltens, P., Pirttilä, T., Wallin, A., Jonhagen, M.E., Minthon, L., Winblad, B., and Blennow, K.

Abstract

Contains fulltext : 80451.pdf (publisher's version ) (Closed access), CONTEXT: Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive impairment (MCI), but large-scale multicenter studies have not been conducted. OBJECTIVE: To determine the diagnostic accuracy of CSF beta-amyloid(1-42) (Abeta42), total tau protein (T-tau), and tau phosphorylated at position threonine 181 (P-tau) for predicting incipient AD in patients with MCI. DESIGN, SETTING, AND PARTICIPANTS: The study had 2 parts: a cross-sectional study involving patients with AD and controls to identify cut points, followed by a prospective cohort study involving patients with MCI, conducted 1990-2007. A total of 750 individuals with MCI, 529 with AD, and 304 controls were recruited by 12 centers in Europe and the United States. Individuals with MCI were followed up for at least 2 years or until symptoms had progressed to clinical dementia. MAIN OUTCOME MEASURES: Sensitivity, specificity, positive and negative likelihood ratios (LRs) of CSF Abeta42, T-tau, and P-tau for identifying incipient AD. RESULTS: During follow-up, 271 participants with MCI were diagnosed with AD and 59 with other dementias. The Abeta42 assay in particular had considerable intersite variability. Patients who developed AD had lower median Abeta42 (356; range, 96-1075 ng/L) and higher P-tau (81; range, 15-183 ng/L) and T-tau (582; range, 83-2174 ng/L) levels than MCI patients who did not develop AD during follow-up (579; range, 121-1420 ng/L for Abeta42; 53; range, 15-163 ng/L for P-tau; and 294; range, 31-2483 ng/L for T-tau, P < .001). The area under the receiver operating characteristic curve was 0.78 (95% confidence interval [CI], 0.75-0.82) for Abeta42, 0.76 (95% CI, 0.72-0.80) for P-tau, and 0.79 (95% CI, 0.76-0.83) for T-tau. Cut-offs with sensitivity set to 85% were defined in the AD and control groups and tested in the MCI group, where the combination of Abeta42/P-tau ratio and T-tau

Published
2009

155. Diagnosing Alzheimer's disease in very elderly patients - Relevance of some functional and psychobehavioral aspects assessed by the Gottfries-Brane-Steen Rating Scale for dementia

Author

Parnetti, L., Brooks, J. O., Pippi, M., Caputo, N., Chionne, F., Senin, U., Abate, G., Pennese, F., Palombo, V., Scurti, R., Azzini, C., Oliani, G., Sangiorgi, G. B., Giordano, M., Bartorelli, L., Monini, P., Martini, T., Tognetti, A., Bonaiuto, S., Cucinotta, D., Marini, G., Tupone, M., Rossi, S., Cuzzupoli, M., Mansoldo, G., Postiglione, A., Milan, G., Andrea Soricelli, Scali, G., Scalisi, P., Marinelli, M. A., Mancinelli, M. D., Mecocci, P., Villardita, C., and Lomeo, C.

Subjects
neuropsychological assessment, senile dementia, Gottfries-Brane-Steen rating scale, aging, factor analysis, Alzheimer's disease
Published
1997

156. 8 Inhibition of COMT reduces cortical motor areas activation in wearing-off Parkinson’s disease patients: An f-MRI study

Author

Tambasco, N., primary, Caproni, S., additional, Chiarini, P., additional, Luchetti, E., additional, Rossi, V., additional, Tarducci, R., additional, Marsili, E., additional, Floridi, P., additional, Sacchini, E., additional, Gallina, A., additional, Muti, M., additional, Parnetti, L., additional, Rossi, A., additional, and Calabresi, P., additional

Published
2012
Full Text
View/download PDF

157. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery

Author

Carlesimo, Ga, Caltagirone, C, Gainotti, Guido, Fadda, L, Gallassi, R, Lorusso, S., Marfia, G, Marra, Camillo, and Parnetti, L.

Subjects
Adult, Aged, 80 and over, Male, Urban Health, Reproducibility of Results, Rural Health, Syndrome, Middle Aged, Neuropsychological Tests, Reference Standards, Sensitivity and Specificity, Settore MED/26 - NEUROLOGIA, Evaluation Studies as Topic, Predictive Value of Tests, Reference Values, 80 and over, Linear Models, Humans, Dementia, Female, Cognition Disorders, Aged
Abstract

This study aimed at investigating the clinical usefulness of the Mental Deterioration Battery (MDB) in the neuropsychological diagnosis and characterization of the dementia syndrome. In this paper, we report: (a) normative data for various test scores derived from the analysis of performance of 340 normal subjects living in urban areas; (b) an evaluation of the reliability of the single tests and of the battery as a whole in differentiating normal subjects from patients affected by cognitive deterioration derived from the analysis of performance of 130 normal subjects living in rural areas and 134 patients affected by probable Alzheimer's dementia; (c) a cluster analysis of performances of the 340 normal subjects in the standardization group to evaluate possible criteria of homogeneity according to which the various MDB scores tend to aggregate; (d) an analysis of performance profiles of 183 patients with right monohemispheric focal lesions, 159 patients with left unilateral lesions with aphasia and 131 left-lesioned nonaphasic patients to evaluate the specificity of the single tests of the battery in documenting a selective impairment of one of the two cerebral hemispheres. Results confirm the reliability of the MBD in discriminating between normal and demented patients and provide indications for use of the battery in differentiating qualitative patterns of cognitive impairment.

Published
1996

158. Age and diagnostic performance of Alzheimer disease CSF biomarkers

Author

Mattsson, N., primary, Rosen, E., additional, Hansson, O., additional, Andreasen, N., additional, Parnetti, L., additional, Jonsson, M., additional, Herukka, S.- K., additional, van der Flier, W. M., additional, Blankenstein, M. A., additional, Ewers, M., additional, Rich, K., additional, Kaiser, E., additional, Verbeek, M. M., additional, Olde Rikkert, M., additional, Tsolaki, M., additional, Mulugeta, E., additional, Aarsland, D., additional, Visser, P. J., additional, Schroder, J., additional, Marcusson, J., additional, de Leon, M., additional, Hampel, H., additional, Scheltens, P., additional, Wallin, A., additional, Eriksdotter-Jonhagen, M., additional, Minthon, L., additional, Winblad, B., additional, Blennow, K., additional, and Zetterberg, H., additional

Published
2012
Full Text
View/download PDF

165. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies

Author

Parnetti, L., primary, Balducci, C., additional, Pierguidi, L., additional, De Carlo, C., additional, Peducci, M., additional, D'Amore, C., additional, Padiglioni, C., additional, Mastrocola, S., additional, Persichetti, E., additional, Paciotti, S., additional, Bellomo, G., additional, Tambasco, N., additional, Rossi, A., additional, Beccari, T., additional, and Calabresi, P., additional

Published
2009
Full Text
View/download PDF

166. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

Author

Verwey, N A, primary, van der Flier, W M, additional, Blennow, K, additional, Clark, C, additional, Sokolow, S, additional, De Deyn, P P, additional, Galasko, D, additional, Hampel, H, additional, Hartmann, T, additional, Kapaki, E, additional, Lannfelt, L, additional, Mehta, P D, additional, Parnetti, L, additional, Petzold, A, additional, Pirttila, T, additional, Saleh, L, additional, Skinningsrud, A, additional, Swieten, J C v, additional, Verbeek, M M, additional, Wiltfang, J, additional, Younkin, S, additional, Scheltens, P, additional, and Blankenstein, M A, additional

Published
2009
Full Text
View/download PDF

168. Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid

Author

Parnetti, L., primary, Ambrosoli, L., additional, Abate, G., additional, Azzini, C., additional, Balestreri, R., additional, Bartorelli, L., additional, Bordin, A., additional, Crepaldi, G., additional, Cristianini, G., additional, Cucinotta, D., additional, Cuzzupoli, M., additional, Candia, O., additional, Fabris, F., additional, Maggioni, M., additional, Scarpa, R., additional, Villardita, C., additional, Girardello, R., additional, Poli, A., additional, and Senin, U., additional

Published
2009
Full Text
View/download PDF

171. Guidelines for the diagnosis of dementia and Alzheimer's disease

Author

Sorbi, S, Alberoni, M, Alfieri, P, Amici, S, Antana, D, Appollonio, I, Avanzi, S, Bartoli, A, Bergamasco, B, Bracco, L, Bruni, A, Bugiani, O, Caffarra, P, Caltagirone, C, Carolei, A, Rosa, A, Ciannella, L, Citterio, A, Daniele, A, D'Achille, G, Del Curatolo, G, Dell'Agnello, G, Durante, D, Farina, E, Ferrero, P, Forleo, P, Gainotti, G, Gabriele, P, Galante, E, Gallai, V, Gallassi, R, Gasparini, M, Ghetti, B, Giaccone, G, Girotti, F, Grimaldi, L, Grioli, S, Guarnieri, B, Grottoli, S, Iemolo, F, Latorraca, S, Le Pira, F, Lenzi, G, Lorusso, S, Mariani, C, Marcon, G, Mascia, V, Mearelli, S, Morante, M, Morbin, M, Musicco, M, Nardelli, E, Nichelli, P, Padovani, A, Paganini, M, Pantieri, R, Parisen, P, Parnetti, L, Passerella, B, Pettenati, C, Piacentini, S, Piccoli, F, Piccolini, C, Pizzolato, G, Provinciali, L, Pugliese, N, Redi, F, Ruggieri, R, Ruggiero, U, Saetta, M, Schoenuber, R, Silveri, M, Sorrentino, G, Sucapane, P, Stracciari, A, Tabaton, M, Tagliavini, F, Toso, V, Valluzzi, F, Guarnieri, BM, Lenzi, GL, Ruggieri, RM, Silveri, MC, Sorbi, S, Alberoni, M, Alfieri, P, Amici, S, Antana, D, Appollonio, I, Avanzi, S, Bartoli, A, Bergamasco, B, Bracco, L, Bruni, A, Bugiani, O, Caffarra, P, Caltagirone, C, Carolei, A, Rosa, A, Ciannella, L, Citterio, A, Daniele, A, D'Achille, G, Del Curatolo, G, Dell'Agnello, G, Durante, D, Farina, E, Ferrero, P, Forleo, P, Gainotti, G, Gabriele, P, Galante, E, Gallai, V, Gallassi, R, Gasparini, M, Ghetti, B, Giaccone, G, Girotti, F, Grimaldi, L, Grioli, S, Guarnieri, B, Grottoli, S, Iemolo, F, Latorraca, S, Le Pira, F, Lenzi, G, Lorusso, S, Mariani, C, Marcon, G, Mascia, V, Mearelli, S, Morante, M, Morbin, M, Musicco, M, Nardelli, E, Nichelli, P, Padovani, A, Paganini, M, Pantieri, R, Parisen, P, Parnetti, L, Passerella, B, Pettenati, C, Piacentini, S, Piccoli, F, Piccolini, C, Pizzolato, G, Provinciali, L, Pugliese, N, Redi, F, Ruggieri, R, Ruggiero, U, Saetta, M, Schoenuber, R, Silveri, M, Sorrentino, G, Sucapane, P, Stracciari, A, Tabaton, M, Tagliavini, F, Toso, V, Valluzzi, F, Guarnieri, BM, Lenzi, GL, Ruggieri, RM, and Silveri, MC

Published
2000

173. Studio PEACE

Author

Scaroni, R., primary, Tambasco, N., additional, Ciorba, E., additional, Parnetti, L., additional, Gallai, V., additional, and Pelliccioli, G.P., additional

Published
2003
Full Text
View/download PDF

178. CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies.

Author

Vanmechelen, E., Van Kerschaver, E., Blennow, K., De Deyn, P. P., Galasko, D., Parnetti, L., Sindic, C. J. M., Arai, H., Riemenschneider, M., Hampel, H., Pottel, H., Valgaeren, A., Hulstaert, F., and Vanderstichele, H.

Subjects
DEMENTIA, NEUROBEHAVIORAL disorders, LEWY body dementia, ALZHEIMER'S disease, BIOMARKERS, CEREBROSPINAL fluid
Abstract

Increased levels of the microtuble-associated protein tau in cerebrospinal fluid is a consistent finding in more than 80% of patients with Alzheimer's disease. As tau protein accumulates in the Alzheimer's disease brain in a hyperphosphorylated form, the determination of phosphorylated tau in cerebrospinal fluid as opposed to total tau might increase the assay specificity. Several recent studies suggest, but do not yet clearly demonstrate, that assays based on phospho-tau are more specific for Alzheimer's disease than those based on total tau. For this reason, the phospho-tau (181P-specific assay) was evaluated in Alzheimer's disease and closely related dementia. Since the relative absence of phosphorylated tau biochemically distinguishes senile dementia with Lewy bodies from Alzheimer's disease, our primary aim was to determine whether there is a significant difference in phospho-tau levels between these two forms of dementia. [ABSTRACT FROM PUBLISHER]

Published
2001

180. Vascular dementia: the role of cerebral infarcts

Author

Leys, D., primary, Erkinjuntti, T., additional, Desmond, D., additional, Schmidt, R., additional, Englund, E., additional, Pasquier, F., additional, Parnetti, L., additional, Ghika, J., additional, Kalaria, R., additional, Chabriat, H., additional, Scheltens, P., additional, and Bogousslavsky, J., additional

Published
2000
Full Text
View/download PDF

196. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.

Author

Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P, Parnetti, Lucilla, Chiasserini, Davide, Eusebi, Paolo, Giannandrea, David, Bellomo, Gianni, De Carlo, Claudia, Padiglioni, Chiara, Mastrocola, Sara, Lisetti, Viviana, and Calabresi, Paolo

Abstract

Mild cognitive impairment (MCI) is a common condition in the elderly which may remain stable along time (MCI-MCI) or evolve into Alzheimer's disease (MCI-AD) or other dementias. Cerebrospinal fluid (CSF) classical biomarkers, i.e., amyloid-β 1-42 (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) reflect the neuropathological changes taking place in AD brains, thus disclosing the disease in its prodromal phase. With the aim to evaluate the power of each biomarker and/or their combination in predicting AD progression, we have measured CSF Aβ1-40, Aβ1-42, t-tau, and p-tau in patients with AD, MCI-MCI, MCI-AD, and other neurological diseases without dementia (OND) followed up for four years. Aβ1-42 levels were significantly lower in AD and MCI-AD than in MCI-MCI. T-tau and p-tau levels were significantly increased in AD and MCI-AD versus OND and MCI-MCI. The Aβ1-42/Aβ1-40 ratio showed a significant decrease in AD and MCI-AD as compared to MCI-MCI. Both Aβ1-42/t-tau and Aβ1-42/p-tau ratios showed significantly decreased values in AD and MCI-AD with respect to OND and MCI-MCI. Aβ1-42/p-tau ratio was the best parameter for discriminating MCI-AD from MCI-MCI (sensitivity 81%, specificity 95%), being also correlated with the annual change rate in the Mini Mental State Examination annual change rate score (MMSE-ACR, rS = -0.71, p < 0.0001). Survival analysis showed that 81% of MCI with a low Aβ1-42/p-tau ratio (<1372) progressed to AD. The best model of logistic regression analysis retained Aβ1-42 and p-tau (sensitivity 75%, 95%CI: 70-80%; specificity 96%, 95%CI: 94-98%). We can conclude that Aβ1-42 and p-tau reliably predict conversion to AD in MCI patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

197. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.

Author

Parnetti, L., Chiasserini, D., Andreasson, U., Ohlson, M., Hüls, C., Zetterberg, H., Minthon, L., Wallin, Å. K., Andreasen, N., Talesa, V. N., and Blennow, K.

Subjects
*ALZHEIMER'S disease treatment, *CEREBROSPINAL fluid, *ACETYLCHOLINESTERASE, *BUTYRYLCHOLINESTERASE, *CLINICAL trials, *PLACEBOS, *FOLLOW-up studies (Medicine), *PHARMACODYNAMICS, *ENZYME inhibitors
Published
2011
Full Text
View/download PDF

198. Cerebrospinal fluid Tau/[alpha]-synuclein ratio in Parkinson's disease and degenerative dementias.

Author

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, and El-Agnaf O

Abstract

Although alpha-synuclein is the main constituent of Lewy bodies, cerebrospinal fluid determination on its own does not seem fundamental for the diagnosis of synucleinopathies. We evaluated whether the combination of classical biomarkers, A[beta](1-42) , total tau, phosphorylated tau, and [alpha]-synuclein can improve discrimination of Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia. A[beta](1-42) , total tau, phosphorylated tau, and [alpha]-synuclein were measured in a series of patients with Parkinson's disease (n = 38), dementia with Lewy bodies (n = 32), Alzheimer's disease (n = 48), frontotemporal dementia (n = 31), and age-matched control patients with other neurological diseases (n = 32). Mean [alpha]-synuclein levels in cerebrospinal fluid were significantly lower in the pathological groups than in cognitively healthy subjects. An inverse correlation of [alpha]-synuclein with total tau (r = -0.196, P < .01) was observed. In the group of patients with Parkinson's disease, A[beta](1-42) , total tau, and phosphorylated tau values were similar to controls, whereas total tau/[alpha]-synuclein and phosphorylated tau/[alpha]-synuclein ratios showed the lowest values. Cerebrospinal fluid [alpha]-synuclein alone did not provide relevant information for Parkinson's disease diagnosis, showing low specificity (area under the curve, 0.662; sensitivity, 94%; specificity, 25%). Instead, a better performance was obtained with the total tau/[alpha]-syn ratio (area under the curve, 0.765; sensitivity, 89%; specificity, 61%). Combined determination of [alpha]-synuclein and classical biomarkers in cerebrospinal fluid shows differential patterns in neurodegenerative disorders. In particular, total tau/[alpha]-synuclein and phosphorylated tau/[alpha]-synuclein ratios can contribute to the discrimination of Parkinson's disease. © 2011 Movement Disorder Society. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

199. A magnetization transfer study of mild and advanced Parkinson's disease.

Author

Tambasco, N., Belcastro, V., Sarchielli, P., Floridi, P., Pierguidi, L., Menichetti, C., Castrioto, A., Chiarini, P., Parnetti, L., Eusebi, P., Calabresi, P., and Rossi, A.

Subjects
PARKINSON'S disease, BRAIN imaging, BASAL ganglia, RED nucleus, SUBSTANTIA nigra, EDEMA, MAGNETIC resonance imaging
Abstract

Magnetization transfer ratio (MTR) technique has identified brain changes in grey and white matter in Parkinson's disease (PD), even in the early phase. However, how these tissue changes differ along the course of the illness is still unclear. This study was aimed at investigating how MTR values change from mild PD (PD1) to patients with advanced PD (PD2). We measured MTR values by region of interest, in 11 PD1, 11 PD2 and 10 healthy age-matched subjects. Compared with controls, patients with PD1 exhibited a significant MTR reduction in substantia nigra pars compacta, substantia nigra pars reticulata, putamen, periventricular white matter and parietal white matter. In addition to the changes observed in PD1, the PD2 group exhibited a significant MTR reduction in caudate, pons, frontal white matter and lateral thalamus. These results suggest that MTR might reflect morphological changes induced by the disease in distinct brain areas at different stages. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results